US2019241611A1PendingUtilityA1
Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment
Est. expiryFeb 20, 2034(~7.6 yrs left)· nominal 20-yr term from priority
A61P 35/00C07D 207/16A61K 45/06C07K 5/1016C07K 5/126A61K 38/12A61K 31/429A61K 31/424
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.
Claims
exact text as granted — not AI-modified1 . A compound of formula 1:
or a pharmaceutically acceptable salt thereof;
wherein
X is S or O;
each Y is independently H or optionally substituted alkyl;
Each R is independently alkyl optionally substituted with OH, OMe, SH, SMe, optionally substituted phenyl, NH 2 , NH-alkyl, or N(alkyl)(alkyl); or each R is independently the side chain of a naturally-occurring or non-natural amino acid;
or wherein each Y and R and the adjacent atoms attached to them (nitrogen and carbon, respectively) can combine to form a heterocyclic ring;
R 1 is optionally substituted alkyl;
R 2 is H or optionally substituted alkyl; and
R 3 is H, optionally substituted alkyl, or —C(O)alkyl.
2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof; according to formula 3:
wherein:
each n is independently 0, 1, 2, 3, or 4; and
each R 5 is independently OH, SH, thioalkoxy, alkoxy, halo, NH 2 , NH-alkyl, or N(alkyl)(alkyl).
3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, of any of formulae:
or a pharmaceutically acceptable salt thereof;
wherein the variables are as defined in claim 1 .
4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is S.
5 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, according to formula 15:
or a pharmaceutically acceptable salt thereof;
wherein the variables are as defined in claim 1 .
6 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, that is:
or a pharmaceutically acceptable salt thereof.
7 .- 18 . (canceled)
19 . A method of treating a subject suffering from or susceptible to a cell proliferation related disorder or disease, comprising administering to said subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, such that said subject is treated for said disorder.
20 . (canceled)
21 . The method of claim 19 , wherein the disorder is cancer, solid tumor, an angiogenesis disorder, or metastatic tumor.
22 .- 37 . (canceled)
38 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
39 . (canceled)
40 . A process to prepare a compound formula 17:
wherein the process comprises the step of reacting a compound of formula 18,
with a compound of formula 19,
to afford a compound of formula 20,
wherein
each X is independently S or O;
each Ri is optionally substituted alkyl;
each R 2 is H;
each R 3 is independently H, optionally substituted alkyl, or —C(O)alkyl;
each R 6 is independently H, optionally substituted alkyl, or —C(O)alkyl;
each R 7 and R 8 are independently H or optionally substituted alkyl; and
each R 9 is independently H, optionally substituted alkyl, or optionally substituted aralkyl.
41 .- 57 . (canceled)
58 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is alkyl.
59 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is methyl.
60 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is H.
61 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is alkyl; and R 2 is H.
62 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is methyl; and R 2 is H.
63 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is
or a pharmaceutically acceptable salt thereof.
64 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, according to Formula 32b:
or a pharmaceutically acceptable salt thereof;
wherein R 1 is optionally substituted alkyl;
R 2 is H or optionally substituted alkyl;
R 3 is H; and
each R 6 is independently H or methyl.
65 . The compound of claim 64 , or a pharmaceutically acceptable salt thereof, wherein R 1 is alkyl.
66 . The compound of claim 64 , or a pharmaceutically acceptable salt thereof, wherein R 1 is methyl.
67 . The compound of claim 64 , or a pharmaceutically acceptable salt thereof, wherein R 1 is alkyl; and R 2 is H.Join the waitlist — get patent alerts
Track US2019241611A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.